Clinical Trial Update: A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma [Phase 3]

View source ↗

Summary

A multicenter, single-arm expanded-access study of lenalidomide plus dexamethasone in previously treated multiple myeloma, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2011-11-03